Afkhami

23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results

Retrieved on: 
Thursday, May 25, 2023
Exercise, GSK, Interim, Total, AACR, Obesity, Diet, Therapy, Table, Marketing, Culture, CD200R1, Stroke, Tax, Pharmacokinetics, Research, PGS, Consumer service, Sale, EBITDA, Patient, Risk, Novartis, Webcast, Afkhami, Consumer, ESG, Poster, Growth, Adjustment, Gene, Disease, Safety, Pharmaceutical industry, CORE (research service)

SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the fourth quarter (Q4) and full year of fiscal year 2023 (FY2023), which ended March 31, 2023. 23andMe is the only company with multiple U.S. Food and Drug Administration (FDA) authorizations for over-the-counter genetic health risk reports. The Company has also created the world’s largest, re-contactable crowdsourced platform of genotypic information paired with billions of phenotypic data points contributed by engaged customers. This unique platform enables the Company to discover new genetic insights, develop impactful risk prediction reports for common health conditions, and accelerate the identification of novel drug discovery programs rooted in human genetics across a spectrum of disease areas.

Key Points: 
  • The results showed 23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable pharmacokinetics and peripheral CD200R1 saturation in patients with advanced solid malignancies.
  • The Phase 2a portion of the study will further characterize the safety, tolerability, pharmacokinetic and pharmacodynamic profile of 23ME-00610.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time on Thursday, May 25, 2023 to discuss the financial results for the full year and Q4 FY2023 and report on business progress.
  • A webcast replay will be available at the same address for a limited time within 24 hours after the event.

Reza Afkhami Joins 23andMe as Chief Corporate Development Officer

Retrieved on: 
Monday, May 8, 2023
Lijun International Pharmaceutical (Holding) Co. Ltd., 23andMe, GSK, University, Therapy, Genetics, Berkeley, Data collection, MBA, Georgetown University, Business administration, Acquisition, Patient, SAN, Drug discovery, Sickle cell disease, Afkhami, Ecosystem, Master of Business Administration, Health, Genome, Disease, Corporate development, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups.
  • 23andMe Therapeutics has a pipeline of genetically validated discovery and clinical programs, which it intends to advance through collaborations with pharmaceutical companies.
  • Furthermore, 23andMe hopes to help the pharmaceutical industry improve its R&D productivity through genetically-driven target identification and portfolio prioritization.
  • Before joining 23andMe, Afkhami was Senior Vice President of Corporate Development and Strategy at Global Blood Therapeutics, a clinical-stage biopharmaceutical company
    focused on innovative therapies for the treatment of sickle cell disease.

Surrozen to Present at Morgan Stanley 18th Annual Global Healthcare Conference

Retrieved on: 
Wednesday, September 16, 2020
Branches of biology, G protein-coupled receptors, Biology, Cell biology, Signal transduction, Frizzled, Wnt signaling pathway, Retinoic acid-inducible orphan G protein-coupled receptor, Afkhami, WNT

SOUTH SAN FRANCISCO, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced that Craig Parker, president and chief executive officer of Surrozen, will participate in a fireside chat at the Morgan Stanley 18th Annual Healthcare Conference.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced that Craig Parker, president and chief executive officer of Surrozen, will participate in a fireside chat at the Morgan Stanley 18th Annual Healthcare Conference.
  • Since its founding in 2016, Surrozen has developed two proprietary platforms to selectively modulate the Wnt pathway for the potential treatment of injury and disease.
  • Surrozen R-spondin-mimetics, also referred to as SWEETS (SurrozenWnt signal enhancers engineered fortissuespecificity), are antibody-based molecules that enhance Wnt signaling by stabilizing Frizzled receptorson targeted cells.
  • Investors/Partners/Media: Reza Afkhami VP, Corporate Development and Strategy Surrozen, Inc. [email protected]

Surrozen Scientific Founder Roel Nusse, PhD Receives Prestigious Canada Gairdner International Award for Biomedical Research

Retrieved on: 
Monday, April 6, 2020
Howard Hughes Medical Investigators, Roel Nusse, Gairdner Foundation, Afkhami, Biology, Branches of biology, Life sciences

The Canada Gairdner Foundation annually designates five outstanding biomedical scientists who have made original contributions to medicine resulting in an increased understanding of human biology and disease.

Key Points: 
  • The Canada Gairdner Foundation annually designates five outstanding biomedical scientists who have made original contributions to medicine resulting in an increased understanding of human biology and disease.
  • Roel Nusse co-founded Surrozen, along with other leaders in Wnt biology, in 2016.
  • The Gairdner Award recognizes Dr. Nusses unique role at the epicenter of our understanding of Wnt biology.
  • Investors/Partners: Reza Afkhami VP, Corporate Development and Strategy Surrozen, Inc. [email protected] Media: Denise Powell Red House Consulting [email protected]